title: Lowering of blood pressure leads to decreased circulating interleukin-6 in hypertensive subjects.
abstract: Interleukin-6 (IL-6), the major proinflammatory cytokine, has been described to be associated with the hypertensive and atherosclerotic states. We aimed to explore whether the concentration of circulating IL-6 and adhesion molecules could be modified by decreasing blood pressure in hypertensive subjects. A total of 30 subjects (18 men), aged 34-48 years, were enrolled in this study, 17 hypertensive never-treated patients (HTA) and 13 normotensive subjects (C). HTA subjects were treated with irbesartan, 150-300 mg/day for 3 months, and serum IL-6, vascular cell adhesion molecule-1, intercellular adhesion molecule-1, sP-selectin, sE-selectin and monocyte chemoattractant protein-1 were measured at 0 and 12 weeks. The two study groups were similar in age, body mass index (BMI) and gender. At baseline, circulating IL-6 levels, but not adhesion molecules, were significantly associated with systolic blood pressure (r=0.41; P=0.03) and BMI (r=0.53; P=0.005). Systolic and diastolic blood pressure decreased significantly (P<0.01) in parallel to serum IL-6 levels (from 3.72+/-0.82 to 3.23+/-0.19 pg/ml, P=0.02) reaching a similar concentration to normotensive patients (3.33+/-0.3 pg/ml) after treatment with irbesartan. No significant changes were observed in any other of the tested parameters. In conclusion, the treatment of high blood pressure lowers circulating IL-6 in young hypertensive patients.
authors.affiliation: Cardiology Unit, Hospital de Blanes, Corporació de Salut del Maresme i La Selva, Girona, Spain. gvazquez@salutms.org
authors.forename: G
authors.initials: G
authors.lastname: Vázquez-Oliva
authors.forename: J M
authors.initials: JM
authors.lastname: Fernández-Real
authors.forename: A
authors.initials: A
authors.lastname: Zamora
authors.forename: M
authors.initials: M
authors.lastname: Vilaseca
authors.forename: L
authors.initials: L
authors.lastname: Badimón
mesh_terms: D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001713:Biphenyl Compounds / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D016022:Case-Control Studies; D015815:Cell Adhesion Molecules / Q000097:blood; D003971:Diastole; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000188:drug therapy*; D015850:Interleukin-6 / Q000097:blood*; D000077405:Irbesartan; D008297:Male; D008875:Middle Aged; D013599:Systole; D013777:Tetrazoles / Q000627:therapeutic use*; D000093242:Interleukin-6 Inhibitors
chemical_list: D000959:Antihypertensive Agents; D001713:Biphenyl Compounds; D015815:Cell Adhesion Molecules; D015850:Interleukin-6; D000077405:Irbesartan; D013777:Tetrazoles; D000093242:Interleukin-6 Inhibitors